Lilly, Resilience commit $750M to boost US diabetes, obesity med production

Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies embark on a $750 million investment to increase production of Lilly’s KwikPen injectable device for its diabetes | Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies plan to invest $750 million to increase production of Lilly’s KwikPen injectable device for its diabetes and obesity medicines Mounjaro and Zepbound.